Enobosarm, also known as ostarine, is an investigational selective androgen receptor modulator (SARM), for the treatment of conditions such as muscle wasting and osteoporosis. Enobosarm has been tested in Phase I, II and III trials with promising results in terms of improving lean body mass and measurements of physical function and power. Enobosarm has received fast-track designation by the United States (US) Food and Drug Administration (FDA). Enobosarm is a SARM with an inhibitory constant (Ki) of 3.8 nM and is tissue-selective for anabolic organs. Enobosarm is in Phase II clinical trials for breast cancer and stress incontinence. The clinical development program for cachexia and muscular atrophy was discontinued. Enobosarm is an investigational drug and therefore not approved for any use by the US FDA. Despite this, it is still sometimes found in dietary supplements, particularly those marketed for bodybuilding. Enobosarm, along with other SARMs, is banned by the World Anti-Doping Agency (WADA) and the National Collegiate Athletic Association (NCAA).
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Enobosarm, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.